Trial register facet
Trial records in hypoactive sexual desire and erectile dysfunction
16 records bearing on hypoactive sexual desire and erectile dysfunction.
Showing 0 records on this page
Records
16 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| RECONNECT-301 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 626 | 2019 | Moderate |
| RECONNECT-302 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 630 | 2019 | Moderate |
| RECONNECT-301-BODY-COMPprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-302-DDIprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Randomised crossover | — | 2019 | Very low |
| RECONNECT-301-REGIONAL-JPprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-302-HEPATIC-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-301-REGIONAL-CNprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-302-RENAL-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-301-QOLprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-302-PKprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-301-ADHERENCEprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Observational | — | 2019 | Very low |
| KISS-PH2-HSDD | Kisspeptin-10 | Phase 2 | Reported | Randomised crossover | 32 | 2017 | Low |
| KISS-PH2-HSDD-BIOMARKERprogramme record | Kisspeptin-10 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| KISS-PH2-HSDD-ADHERENCEprogramme record | Kisspeptin-10 | Phase 2 | Reported | Observational | — | 2017 | Very low |
| KISS-PH2-HSDD-OLEprogramme record | Kisspeptin-10 | Phase 2 | Reported | Single-arm open-label | — | 2017 | Very low |
| KISS-PH2-HSDD-ELDERLYprogramme record | Kisspeptin-10 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |